Evidence map›Paper›PMID 31617560›Full record

ArticleNucleic acids research2019

HER3-targeted protein chimera forms endosomolytic capsomeres and self-assembles into stealth nucleocapsids for systemic tumor homing of RNA interference in vivo.

Felix Alonso-Valenteen, Sayuri Pacheco, Dustin Srinivas, Altan Rentsendorj, David Chu, Jay Lubow, Jessica Sims, Tianxin Miao, Simoun Mikhael, Jae Youn Hwang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Felix Alonso-ValenteenDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Sayuri PachecoDepartment of Chemistry and Biochemistry, California State University, Northridge, CA 91330, USA.
Dustin SrinivasDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Altan RentsendorjDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
David ChuDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Jay LubowDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Jessica SimsDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Tianxin MiaoDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Simoun MikhaelDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Jae Youn HwangDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Ravinder AbrolDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Lali K Medina KauweDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Cedars-Sinai Medical Center · USCalifornia State University, Northridge · US

Funding

BUILD PODER IITL4GM118977 · NIGMS · CALIFORNIA STATE UNIVERSITY NORTHRIDGE · PI CHAVIRA, GABRIELA, KHACHIKIAN, CRIST SIMON · 2015 to 2023
$18.1M
Project-002UL1GM118976 · NIGMS · CALIFORNIA STATE UNIVERSITY NORTHRIDGE · PI SAETERMOE, CARRIE L · 2015 to 2023
$7.8M
Tumor Targeted Corroles for Detection and InterventionR01CA140995 · NCI · CEDARS-SINAI MEDICAL CENTER · PI MEDINA-KAUWE, LALI K · 2010 to 2021
$3.7M
Protein-DNA Drug Carriers for Tumor TargetingR01CA129822 · NCI · CEDARS-SINAI MEDICAL CENTER · PI MEDINA-KAUWE, LALI K · 2009 to 2020
$3.0M
Targeting inhibitor-resistant breast tumors with HER3-homing nano-capsidsR01CA258204 · NCI · CEDARS-SINAI MEDICAL CENTER · PI LALI K MEDINA-KAUWE · 2022 to 2026
$1.9M
Nucleocapsid bioparticles eliciting multi-pronged attack on tumor metastasesR01CA270324 · NCI · CEDARS-SINAI MEDICAL CENTER · PI LALI K MEDINA-KAUWE · 2022 to 2026
$1.5M
Multidisciplinary Pulmonary Research Training ProgramT32HL134637 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI NOBLE, PAUL WESLEY · 2017 to 2021
$1.3M
NCI NIH HHS R01 CA129822NCI NIH HHS R01 CA140995NCI NIH HHS R01 CA258204NCI NIH HHS R01 CA270324NHLBI NIH HHS T32 HL134637NIGMS NIH HHS TL4 GM118977NIGMS NIH HHS UL1 GM118976
6 · The paper itself

Abstract

RNA interference represents a potent intervention for cancer treatment but requires a robust delivery agent for transporting gene-modulating molecules, such as small interfering RNAs (siRNAs). Although numerous molecular approaches for siRNA delivery are adequate in vitro, delivery to therapeutic targets in vivo is limited by payload integrity, cell targeting, efficient cell uptake, and membrane penetration. We constructed nonviral biomaterials to transport small nucleic acids to cell targets, including tumor cells, on the basis of the self-assembling and cell-penetrating activities of the adenovirus capsid penton base. Our recombinant penton base chimera contains polypeptide domains designed for noncovalent assembly with anionic molecules and tumor homing. Here, structural modeling, molecular dynamics simulations, and functional assays suggest that it forms pentameric units resembling viral capsomeres that assemble into larger capsid-like structures when combined with siRNA cargo. Pentamerization forms a barrel lined with charged residues mediating pH-responsive dissociation and exposing masked domains, providing insight on the endosomolytic mechanism. The therapeutic impact was examined on tumors expressing high levels of HER3/ErbB3 that are resistant to clinical inhibitors. Our findings suggest that our construct may utilize ligand mimicry to avoid host attack and target the siRNA to HER3+ tumors by forming multivalent capsid-like structures.

Indexed as

AnimalsCapsid ProteinsCell Line, TumorDrug CarriersHumansMiceMice, Inbred BALB CNanoparticlesNeuregulin-1Receptor, ErbB-3Recombinant ProteinsRNA InterferenceRNA, Small InterferingCapsid ProteinsDrug CarriersERBB3 protein, humanErbB3 protein, mouseheregulin alphahexon capsid protein, AdenovirusNeuregulin-1Receptor, ErbB-3Recombinant ProteinsRNA, Small Interfering

Identifiers

PMID31617560
PMCPMC6868389
OpenAlexW2980424604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.